Related Experiment Video
Updated: May 16, 2025
Evaluation of Hepatic Glucose Production in a Polycystic Ovary Syndrome Mouse Model
Published on: March 5, 2022
Exploring Biomarkers Related to Cell Adhesion in Polycystic Ovary Syndrome Using Bioinformatics and Conducting
Jiani Zhu1,2, Xinyue Qi3,4, Zhenyu Zhang1,2
1Department of Clinical Nutrition, The First People's Hospital of Yunnan Province, Kunming, Yunnan, People's Republic of China.
Purpose:
Related studies have pointed out that cell adhesion may play an important role for treating Polycystic Ovary Syndrome (PCOS). This study aimed to identify and analyze the biomarkers associated with cell adhesion-related genes (CRGs) for treating PCOS and their biological mechanisms.
Patients And Methods:
In this study, GSE80432 was used to identify differentially expressed genes (DEGs) (PCOS vs control group) through differential expression analysis. Then, the DEGs were overlapped with 1531 CRGs to obtain the cross - genes. Subsequently, the Support Vector Machine-Recursive Feature Elimination combined with the least absolute shrinkage and selection operator was utilized to obtain candidate genes, and the genes with AUC greater than 0.7 and consistent expression trends in the two datasets were defined as biomarkers. Finally, a nomogram was constructed, and enrichment analysis, regulatory network, drug prediction, the association between biomarkers and PCOS, and reverse transcription quantitative PCR (RT-qPCR) were carried out respectively.
Results:
A total of 10 cross-genes were identified, and 2 biomarkers (DSG2 and TH11) were screened out from them. RT-qPCR analysis showed that the expression of THBS1 was increased in PCOS samples, while there was no significant difference in DSG2. In addition, enrichment analysis indicated that both DSG2 and THBS1 were enriched in the B-cell receptor signaling pathway. Then, based on these two biomarkers, lncRNA-miRNA-mRNA (81 nodes and 135 edges) and TFs biomarker networks (38 nodes and 38 edges), such as MIR17HG'-has-miR-7-5p'-THBS1, TFDP1-DSG2, were constructed respectively. By predicting drugs targeting biomarkers, 61 drugs were predicted to target DSG2, while 133 drugs were predicted to target THBS1. Moreover, a stronger association between THBS1 and PCOS was detected (inference score = 27.15).
Conclusion:
In this study, 2 biomarkers (DSG2 and THBS1) were identified, providing a potential theoretical basis for PCOS treatment.
Insights
This study identified DSG2 and THBS1 as potential biomarkers for Polycystic Ovary Syndrome (PCOS) treatment. These cell adhesion-related genes offer a new theoretical basis for understanding and managing PCOS.
Area of Science:
- Genomics and Molecular Biology
- Endocrinology
- Biomarker Discovery
Background:
- Cell adhesion is implicated in Polycystic Ovary Syndrome (PCOS) pathogenesis.
- Identifying specific biomarkers related to cell adhesion can advance PCOS treatment strategies.
Purpose of the Study:
- To identify and analyze cell adhesion-related genes (CRGs) as biomarkers for PCOS.
- To elucidate the biological mechanisms underlying these potential PCOS biomarkers.
Main Methods:
- Differential gene expression analysis of GSE80432 dataset (PCOS vs. control).
- Overlap analysis with 1531 CRGs to identify cross-genes.
- Machine learning (SVM-RFE, LASSO) for biomarker selection (AUC > 0.7).
- Construction of nomograms, enrichment analysis, regulatory networks, and drug prediction.
- Validation using reverse transcription quantitative PCR (RT-qPCR).
Main Results:
- Two candidate biomarkers, DSG2 and THBS1, were identified from 10 cross-genes.
- THBS1 expression was significantly increased in PCOS samples.
- Both DSG2 and THBS1 were enriched in the B-cell receptor signaling pathway.
- Regulatory networks and potential drug targets for DSG2 and THBS1 were established.
- THBS1 showed a strong association with PCOS (inference score = 27.15).
Conclusions:
- DSG2 and THBS1 are identified as potential biomarkers for Polycystic Ovary Syndrome (PCOS).
- These findings provide a theoretical foundation for developing novel PCOS therapeutic approaches.
- Further research into the roles of DSG2 and THBS1 in PCOS is warranted.
